Navigation Links
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Date:9/17/2007

iovascular safety (including atrial fibrillation), found Reclast to be comparable with placebo. Incidence of renal events were similar between the Reclast and placebo group (6.2% versus 5.6%, respectively). Atrial fibrillation serious adverse events occurred in 1.1% of Reclast-treated patients compared to 1.3% of placebo- treated patients. No cases of osteonecrosis of the jaw (ONJ) were seen in the study. The most common adverse events with Reclast were transient post-dose symptoms (such as fever, muscular pain, etc).

About the Study

The Recurrent Fracture Trial was an international, multi-center, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of Reclast in preventing subsequent fractures in men and women following the surgical repair of a low-trauma hip fracture (i.e., a fall from standing height or less or equivalent force).

It is part of the Novartis HORIZON clinical trial program, one of the most comprehensive drug evaluation programs ever undertaken in the area of metabolic bone diseases involving 13,000 patients in more than 400 centers worldwide.

Men and women between the ages of 50 and 98 who had experienced a recent hip fracture sustained with minimal trauma were randomized to receive a once- yearly infusion of Reclast or placebo within 90 days of undergoing surgery to repair the hip fracture and every 12 months thereafter for up to three years.

The primary endpoint of the study was to determine the effect of Reclast on new clinical fractures following baseline hip fracture. Secondary endpoints included the change in bone mineral density (BMD) in the non- fractured hip measured annually; spine, non-spine and hip fractures; and pre- specified safety endpoints, including death.

About Reclast

Reclast was approved by the US Food and Drug Administration (FDA) on August 17, 2007 as the first and only once-yearly treatment for postmenopausal osteoporosis. Approval
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Nov. 1, 2010 LitePoint Corporation, the leader in ... Health Alliance, along with other technology leaders. ... of personal healthcare and to establish a system of ... for all people. "Wireless will be ...
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
Cached Medicine Technology:LitePoint Joins Continua Health Alliance 2China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2
(Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
(Date:12/17/2014)... Amy Norton HealthDay ... Yoga has long been believed to improve overall health, but ... also help the heart, a new review finds. In ... such as brisk walking, said lead researcher Paula Chu, a ... The review, of 37 clinical trials, found that people ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic ... JM Ocean Avenue has secured exclusive benefit to the ... system. JM Ocean Avenue is a direct sales ... Avenue and JM International, with partial ownership coming from ... company. , “After nearly 2 decades of servicing the ...
(Date:12/15/2014)... MD (PRWEB) December 15, 2014 ... services today released “ Social Media Cheat Sheets ,” ... a community that drives results on the top ten ... marketing program. It helps drive awareness, engagement, and customer ... For marketers to make an impact on new networks ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... researchers from the University at Buffalo School of Dental ... X-ray// may serve as an accurate early-warning system of ... ,The study was ushered in a population with a ... us closer to the use of panoramic dental radiographs ...
... that people become addicted to nicotine by smoking regularly over ... be more disturbing. According to a Canadian study, young people ... no more than a few cigarettes a month. ,Using ... young people in their first year of high school to ...
... know when someone who talks about suicide will actually ... which depressed patients need protection.Now American scientists believe that// ... blood test that checks glands controlling the stress hormone ... to the mental turmoil that leads people to take ...
... report they have identified a genetic defect that causes a ... bone, a finding that may lead to treatments for osteoporosis. ... mineral center at Hopkins University, the new finding will help ... make new bone cells as people age.// ,Later, ...
... food poisonings aren't going away, despite the efforts of ... imported foods and bacteria develop in new forms, according ... The bacteria Listeria monocytogenes are so common in the ... of them. ,The scientists also say the ...
... for Disease Control and Prevention (CDC) say that tobacco ... caries and tobacco use data from more than// 13,000 ... between the two types of spit tobacco, also called ... cigarettes, pipes, and cigars. Spit tobacco comes in two ...
Cached Medicine News:Health News:Mutation connected to Osteoporosis 2
... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Galilean Loupes...
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
Medicine Products: